Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's New Legal Power To Limit Or Block Mergers Could Signal Challenges Ahead For Global Pharmaceutical Alliances

This article was originally published in PharmAsia News

Executive Summary

BEIJING - The Chinese Ministry of Commerce's wielding of a new Anti-Monopoly Law to block Coca-Cola's purchase of a local juice producer, and to impose severe restrictions on the combination of two other international businesses, could signal troubled times ahead for any global outfit operating in China that seeks to expand through a merger
Advertisement

Related Content

More Barriers To Entry For M&A In China? Novartis Case Provides Some Clarity
More Barriers To Entry For M&A In China? Novartis Case Provides Some Clarity
GSK Finalizes Acquisition Of Nanjing Meirui For $70 Million
Novartis Tagged With Anti-monopoly Conditions In China For Alcon Acquisition
Acquisitions Catapult China Biologic Into Leading Biopharma Outfit; Position It For Global Competition With U.S., EU Players
Pfizer’s New Org Chart Brings Eight Wyeth Execs Topside
68 Billon Dollar Question: Could China's Government Block Worldwide Merger Of Wyeth And Pfizer?
In Wake Of Heparin Deaths, FDA Set To Launch Pilot Project Aimed At Preventing Imports Of Adulterated Drugs
Global Pharma Giants Concered About China’s New Anti-Monopoly Law
Global Pharma Giants Concered About China’s New Anti-Monopoly Law
Advertisement
UsernamePublicRestriction

Register

SC071443

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel